- Home
- GGAL vs RGEN Comparison
GGAL vs RGEN Comparison
Compare GGAL & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGAL
- RGEN
- Stock Information
- Founded
- GGAL 1905
- RGEN 1981
- Country
- GGAL Argentina
- RGEN United States
- Employees
- GGAL N/A
- RGEN N/A
- Industry
- GGAL Commercial Banks
- RGEN Medical/Dental Instruments
- Sector
- GGAL Finance
- RGEN Health Care
- Exchange
- GGAL Nasdaq
- RGEN Nasdaq
- Market Cap
- GGAL 7.1B
- RGEN 7.4B
- IPO Year
- GGAL N/A
- RGEN N/A
- Fundamental
- Price
- GGAL $61.45
- RGEN $142.39
- Analyst Decision
- GGAL Strong Buy
- RGEN Buy
- Analyst Count
- GGAL 4
- RGEN 12
- Target Price
- GGAL $59.00
- RGEN $175.56
- AVG Volume (30 Days)
- GGAL 1.7M
- RGEN 954.4K
- Earning Date
- GGAL 01-01-0001
- RGEN 04-29-2025
- Dividend Yield
- GGAL 3.81%
- RGEN N/A
- EPS Growth
- GGAL 120.03
- RGEN N/A
- EPS
- GGAL 1.06
- RGEN N/A
- Revenue
- GGAL $6,697,505,438.00
- RGEN $634,439,000.00
- Revenue This Year
- GGAL $9.54
- RGEN $12.61
- Revenue Next Year
- GGAL N/A
- RGEN $15.24
- P/E Ratio
- GGAL $6.60
- RGEN N/A
- Revenue Growth
- GGAL N/A
- RGEN 0.33
- 52 Week Low
- GGAL $23.53
- RGEN $102.97
- 52 Week High
- GGAL $74.00
- RGEN $182.52
- Technical
- Relative Strength Index (RSI)
- GGAL 56.41
- RGEN 53.16
- Support Level
- GGAL $61.67
- RGEN $125.05
- Resistance Level
- GGAL $66.24
- RGEN $148.38
- Average True Range (ATR)
- GGAL 3.49
- RGEN 8.43
- MACD
- GGAL 0.79
- RGEN 2.84
- Stochastic Oscillator
- GGAL 81.25
- RGEN 77.58
About GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.